Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.52 |
| ▸ | THRB | P10828 | 12/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214212 | 0.92 | THRA (0.54) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL3153210 | 0.92 | THRA (0.62) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL13703154 | 0.88 | THRA (0.47) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL3149161 | 0.88 | THRA (0.49) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL3149062 | 0.87 | THRA (0.51) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL4215935 | 0.85 | THRA (0.49) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL4215939 | 0.81 | PTGS1 (0.42) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL1458123 | 0.81 | THRB (0.54) | THRATHRBESR1ESR2MAPT | |
| SCHEMBL13399172 | 0.81 | THRA (0.45) | THRATHRBPTGS1PTGS2ESR1 | |
| SCHEMBL281929 | 0.81 | THRA (0.63) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | THRA 2/4885THRB 4/4885PTGS1 871/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRA 14/4885THRB 41/4885PTGS1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.